Azafaros announces promotion of Dr Anke Arnold-Tugulu to Chief Regulatory Officer

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium

Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

Azafaros Appoints Chief Operating Officer and Head of Finance

Beyond Biotech podcast 35: Rare Disease Day

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

Azafaros expands executive management team and operations

Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders